These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27222025)

  • 1. Surface-Modified Liposomal Formulation of Amphotericin B: In vitro Evaluation of Potential Against Visceral Leishmaniasis.
    Patere SN; Pathak PO; Kumar Shukla A; Singh RK; Kumar Dubey V; Mehta MJ; Patil AG; Gota V; Nagarsenker MS
    AAPS PharmSciTech; 2017 Apr; 18(3):710-720. PubMed ID: 27222025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid-polymer hybrid nanoparticle: biodistribution and toxicity assessment of encapsulated amphotericin B.
    Asthana S; Jaiswal AK; Gupta PK; Dube A; Chourasia MK
    Eur J Pharm Biopharm; 2015 Jan; 89():62-73. PubMed ID: 25477079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mannosylated liposomes bearing Amphotericin B for effective management of visceral Leishmaniasis.
    Rathore A; Jain A; Gulbake A; Shilpi S; Khare P; Jain A; Jain SK
    J Liposome Res; 2011 Dec; 21(4):333-40. PubMed ID: 21612342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol anchored arabinogalactan for asialoglycoprotein receptor targeting: synthesis, characterization, and proof of concept of hepatospecific delivery.
    Pathak PO; Nagarsenker MS; Barhate CR; Padhye SG; Dhawan VV; Bhattacharyya D; Viswanathan CL; Steiniger F; Fahr A
    Carbohydr Res; 2015 May; 408():33-43. PubMed ID: 25841057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
    Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
    Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis.
    Khatik R; Dwivedi P; Khare P; Kansal S; Dube A; Mishra PR; Dwivedi AK
    Expert Opin Drug Deliv; 2014 May; 11(5):633-46. PubMed ID: 24606222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis.
    Gupta PK; Asthana S; Jaiswal AK; Kumar V; Verma AK; Shukla P; Dwivedi P; Dube A; Mishra PR
    Bioconjug Chem; 2014 Jun; 25(6):1091-102. PubMed ID: 24842628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies.
    Asthana S; Gupta PK; Jaiswal AK; Dube A; Chourasia MK
    Pharm Res; 2015 Aug; 32(8):2663-77. PubMed ID: 25715698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
    Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
    J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies.
    Asthana S; Gupta PK; Jaiswal AK; Dube A; Chourasia MK
    Nanomedicine (Lond); 2015; 10(7):1093-109. PubMed ID: 25929567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis.
    Chaurasia M; Singh PK; Jaiswal AK; Kumar A; Pawar VK; Dube A; Paliwal SK; Chourasia MK
    Pharm Res; 2016 Nov; 33(11):2617-29. PubMed ID: 27401407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand directed macrophage targeting of amphotericin B loaded liposomes.
    Vyas SP; Katare YK; Mishra V; Sihorkar V
    Int J Pharm; 2000 Dec; 210(1-2):1-14. PubMed ID: 11163983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach.
    Manandhar KD; Yadav TP; Prajapati VK; Basukala O; Aganja RP; Dude A; Shrivastav ON; Sundar S
    Adv Exp Med Biol; 2014; 808():77-91. PubMed ID: 24595612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
    Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
    Coukell AJ; Brogden RN
    Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model.
    Mishra J; Dey A; Singh N; Somvanshi R; Singh S
    Indian J Med Res; 2013 Apr; 137(4):767-76. PubMed ID: 23703346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileishmanial activity of nano-amphotericin B deoxycholate.
    Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
    J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.